Connect with us

/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

IHOP® Unveils Three New, All-Natural, Black Angus Beef Pancakes (Which Are Actually Burgers)

Published

on

Reading Time: 4 minutes

One Year after IHOb Campaign Sensation, the Brand Listens to the
Internet and Sticks to What it Knows Best: Pancakes

GLENDALE, Calif.–(BUSINESS WIRE)–Last year, IHOP introduced the award-winning IHOb – for burgers –
advertising campaign and the Internet had a lot to say about it. It told
IHOP to stay in their lane. To stick to pancakes. So, this year, IHOP is
taking the Internet’s advice by calling their new Steakburgers
“Pancakes.”

Launching today, the line-up of all-natural, 100% USDA Choice, Black
Angus beef Pancakes features three new, enticing flavors: The Garlic
Butter “Pancake”, The Loaded Philly “Pancake”, and The Big IHOP
“Pancake”, a “Pancake” with a pancake in it. The Big IHOP Pancake
Burger™ includes a hot, fluffy, cheddar cheese pancake layered between
two juicy beef patties, melted American cheese, crisp bacon and
house-made IHOP sauce, but it’s only available for a limited time. Each
“Pancake” is made with all-natural, 100% USDA choice, Black Angus beef,
smashed on the grill to sear in the juices, hand-seasoned and piled high
with premium ingredients. And, for a limited time, all Pancakes (we mean
Steakburgers) will be served with unlimited fries, starting at $6.99*.

That’s right, IHOP is following up on last year’s successful Ultimate
Steakburger launch with a playful twist that again shows that it takes
its burgers as seriously as it takes it pancakes. After temporarily
changing its name to IHOb – for The International House of Burgers – a
heated debate across social media ensued, with some die-hard pancake
fans taking to Twitter to make it known that they wanted IHOP to “stay
in its lane.” So, this June, the brand is, in fact, sticking to pancakes
by renaming its Ultimate Steakburgers for a limited-time with a line-up
that includes:

  • The Big IHOP Pancake (Burger)™: A world-famous buttermilk
    pancake griddled with Cheddar cheese and layered between two premium
    Steakburger patties, then topped with American cheese, custom-cured
    hickory-smoked bacon and house-made IHOP sauce.
  • Garlic Butter Pancake (Steakburger): Topped with savory
    house-made Gilroy garlic butter, custom-cured hickory-smoked bacon,
    White Cheddar cheese, fresh lettuce, tomato, onion and mayo.
  • Loaded Philly Pancake (Steakburger): Piled high with sautéed
    onions and peppers and smothered with melted White Cheddar cheese and
    Cheddar cheese sauce.

“When we launched our new Ultimate Steakburgers last year, what better
way to show the world that we take our burgers as seriously as we take
our pancakes than by announcing that we’d be changing our name to IHOb …
temporarily,” said Brad Haley, Chief Marketing Officer at IHOP. “That
was hard for a lot of people to accept since they’d always known IHOP
primarily as the breakfast and pancake place, so they took to social
media to tell us – often in no uncertain terms – to stay in our lane and
stick to pancakes. But we made our all-natural, 100% USDA Choice, Black
Angus beef Steakburgers good enough to stand up to the best burgers out
there and we sold a lot of them: initially four times what we sold
before, and they are still selling double what we sold before. So, we’re
listening to the Internet this year by calling our new Steakburgers
‘Pancakes.’ And, so many people asked us why we didn’t have a pancake
burger last year that we’ve even added a ‘Pancake’ with a pancake in it:
The Big IHOP Pancake … Burger.”

In addition to referring to their new burgers as “Pancakes,” IHOP is
taking things a step further by creating a digital experience that aims
to get reluctant burger-lovers onboard with their new approach.

“There were over 3.3 million tweets about #IHOb last year, and some of
them weren’t very nice,” Haley added. “So, our lead creative agency,
Droga5, created a digital experience to engage last year’s naysayers and
convert haters into eaters. Those who tweeted something, shall we say,
unkind last year may find that they’re on The Bancake List, an
aggregated list of Twitter users who tweeted at IHOP to stay in its
lane. Fortunately, there is a way to get off The Bancake List – all they
have to do is tweet something nice about IHOP’s Pancakes/Burgers, and
they’ll be removed from the list. To make it even easier, we’re
providing very funny options people can choose from if they don’t want
to create their own and, best of all, they could even be rewarded with a
token of the brand’s appreciation. Users can visit BancakeList.com to
find out whether they or their friends are on The Bancake List, and how
to get off of it. Of course, we’ll also be engaging many of those guests
who were instant fans of our Steakburgers last year.”

The new Steakburger line-up joins IHOP’s original burger flavors,
including The Classic, The Classic with Bacon, Mega Monster, Cowboy BBQ,
The Big Brunch and Jalapeno Kick. Pancakes – the meaty kind or the
fluffy kind — are both best enjoyed with IHOP’s new House-Made
Milkshakes. Recently introduced at all IHOP restaurants, House-Made
Milkshakes are made with hand-scooped, premium, natural vanilla ice
cream, with real milk and whipped topping, and are available in five
craveable flavors: HERSHEY’s Chocolate, Strawberry, OREO® Cookie,
Cold-Brew Coffee and Vanilla.

Guests can visit IHOP.com
to find their nearest IHOP restaurant and learn more about the new
lineup of all-natural, 100% USDA choice Black Angus ‘Pancakes’ and to
see if they are on The Bancake List.

*Price and participation may vary. Offer only available for a limited
time. Dine-in only.

**A select number of rewards will be available. Participating in or
being listed on the Bancake website does not guarantee a prize.

OREO® and the OREO® Wafer Design are trademarks of Mondelez
International group, used under license.

The HERSHEY’S trademark is used under license from The Hershey
Company.

ABOUT INTERNATIONAL HOUSE OF PANCAKES, LLC

For over 60 years, IHOP has been a leader, innovator and expert in all
things breakfast, any time of day. The chain offers 65 different
signature, fresh, made-to-order breakfast options, a wide selection of
popular lunch and dinner items, including Ultimate Steakburgers. IHOP
restaurants offer guests an affordable, everyday dining experience with
warm and friendly service. As of December 31, 2018, there are 1,831 IHOP
restaurants around the world, including restaurants in all 50 states and
the District of Columbia, Puerto Rico and Guam as well as Canada,
Mexico, Guatemala, Panama, Lebanon, the Kingdom of Saudi Arabia, Kuwait,
the United Arab Emirates, Bahrain, Qatar, Thailand and India. IHOP
restaurants are franchised by affiliates of Glendale, Calif.-based Dine
Brands Global, Inc. (NYSE: DIN).

Contacts

Sami Newman
DeVries Global
+ 1 212-546-8510
[email protected]


Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Cannabis

Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care

Published

on

Continue Reading

Innocan

Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain

Published

on

innocan-pharma-initiates-fda-approval-process-for-liposome-injection-therapy-for-chronic-pain

With its submission of a Pre-IND Meeting Request Letter, Innocan initiates the regulatory process with the U.S. Food and Drug Administration (FDA) for the approval of its prolonged CBD release technology for human use

HERZLIYA, Israel and CALGARY, AB, April 22, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), is pleased to announce that is has reached a key milestone: the Company submitted its letter of application for a Pre-IND meeting, the first phase in the FDA approval process in the United States for Innocan’s Liposome-Cannabidiol (LPT-CBD) injectable treatment of chronic pain.

With the global market for pain therapeutics widely expected to exceed US$100 billion by 2032[1], LPT therapy which requires only one single monthly subcutaneous injection, is positioned as a highly attractive alternative to opioid-based approaches. Opioids have and continue to take a significant human toll in recent years, with more than three-quarters of drug overdose deaths in the United States involving opioids, according to the United States Center for Disease Control and Prevention[2].

Innocan’s therapy has shown consistent efficacy in multiple pre-clinical trials in recent years of it’s LPT-CBD injectable treatment through prolonged and controlled release of CBD in animals with chronic pain conditions. Innocan’s Pre-IND Meeting Request Letter to the FDA is a key milestone and important first step in seeking approval of its LPT-CBD therapy for use in humans. At the Pre-IND meeting, the objective will be to obtain guidance from the FDA on the preclinical and clinical development plan, enabling the initiation of an Investigational New Drug (IND) program in the United States.

Iris Bincovich, CEO of Innocan, commented: “We are extremely excited to embark on this next stage in the development of LPT-CBD injectables, this is a major Milestone for Innocan Pharma. We have invested significant effort and many thousands of person-hours in its research and development, accumulating a wealth of preclinical data that will serve as the foundation for our participation in the FDA process. This is a key milestone for Innocan and marks our first step towards the FDA’s recognition of our technology. We see significant potential for our therapy, with an addressable market for pain management therapeutics expected to exceed US $100 billion by 2032, and we look forward to tapping that.

Dr. Joseph Pergolizzi, Innocan’s FDA Advisory Board Member, added:

“We have worked hard to catalogue the data collected as part of our animal LPT therapy testing program and prepare it for the FDA. We look forward to working under FDA guidance, with the goal of completing the review process as quickly and efficiently as possible. We believe that Innocan’s unique treatment method, if and when it should become FDA-approved has the potential of being a highly valuable non-opioid addition in the medical arsenal of the management of chronic pain.”

About Innocan

Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies based on advanced cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD- loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for: Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment, Innocan has established a joint venture by the name of BI Sky Global Ltd. that focuses on advanced targeted online sales. https://innocanpharma.com/

For further information, please contact:

For Innocan Pharma Corporation:
Iris Bincovich, CEO

+1-516-210-4025

+972-54-3012842

+442037699377
[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Cautionary note regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding research and development, collaborations, the filing of potential applications with the FDA and other regulatory authorities, the potential achievement of future regulatory milestones, the potential for treatment of conditions and other therapeutic effects resulting from research activities and/or the Company’s products, requisite regulatory approvals and the timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

[1] https://www.gminsights.com/industry-analysis/pain-management-drugs-market

[2] https://www.cdc.gov/opioids/data/index.html

Logo – https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-initiates-fda-approval-process-for-liposome-injection-therapy-for-chronic-pain-302122779.html

Continue Reading

Curaleaf

Curaleaf Completes Acquisition of Northern Green Canada

Published

on

curaleaf-completes-acquisition-of-northern-green-canada

Bolsters Company’s Advantage in Several Key Emerging Markets, including Australia, New Zealand, Germany, Poland and the United Kingdom

NEW YORK, April 22, 2024 /PRNewswire/ — Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading international provider of consumer cannabis products, announced today the closing of its acquisition of Northern Green Canada (“NGC”), a vertically integrated Canadian licensed cannabis producer focused primarily on expanding in the international market through its EU-GMP certification. The accretive acquisition amplifies the Company’s strategic advantage in established European markets including Germany, Poland and the United Kingdom and provides a foothold in the emerging markets of Australia and New Zealand.

Integrating NGC’s international operation will equip Curaleaf with a secure and consistent high quality, non-irradiated, indoor EU-GMP flower supply, essential to maintaining its leading positions in Germany, the United Kingdom and Poland.

“We are thrilled to welcome NGC formally to the Curaleaf family of global brands,” said Boris Jordan, Founder and Executive Chairman of Curaleaf. “This is an incredibly important deal for our international expansion strategy, as we’ll be able to bolster our supply of high quality EU-GMP certified flower immediately to key European markets as well as enter the fast-growing markets of Australia and New Zealand.”

The global cannabis market is projected to generate $55 billion in sales by 2027. Emerging markets beyond the United States and Canada, including Germany, Australia and New Zealand are expected to contribute $6.3 billion of the $55 billion projection.

Terms of the acquisition of NGC include an initial payment at closing of the Company’s Subordinate Voting Shares valued at approximately US $16 million, subject to a typical post-closing adjustment. An earnout may also be paid in 2025 based upon 2024 performance of NGC’s operations, up to 50% of which will be cash and the rest paid in additional Subordinate Voting Shares. The issuance of Subordinate Voting Shares in connection with the acquisition of NGC has been conditionally approved by the Toronto Stock Exchange, subject to fulfilling customary listing conditions.

About Curaleaf Holdings
Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) (“Curaleaf”) is a leading international provider of consumer products in cannabis with a mission to enhance lives by cultivating, sharing and celebrating the power of the plant. As a high-growth cannabis company known for quality, expertise and reliability, the Company and its brands, including Curaleaf, Select, Grassroots, JAMS, Find and Zero Proof provide industry-leading service, product selection and accessibility across the medical and adult use markets. Curaleaf International is the largest vertically integrated cannabis company in Europe with a unique supply and distribution network throughout the European market, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. Curaleaf is listed on the Toronto Stock Exchange under the symbol CURA and trades on the OTCQX market under the symbol CURLF. For more information, please visit https://ir.curaleaf.com.

Forward Looking Statements
This media advisory contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward–looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans”, “expects” or, “proposed”, “is expected”, “intends”, “anticipates”, or “believes”, or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. More particularly and without limitation, this news release contains forward-looking statements and information concerning the expected benefits of the acquisition of NGC, and the Company’s planned expansion on internal markets, the Company’s anticipated strategic advantages in European markets and emerging markets, the integration of NGC’s internal operations, the anticipated global cannabis market, and the listing of shares issuable in connection with the acquisition on the Toronto Stock Exchange. Such forward-looking statements and information reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company with respect to the matters described in this new release, including the Company’s ability to successfully realize the expected benefits of the acquisition, and the Company’s ability to fulfil the listing conditions imposed by the Toronto Stock Exchange. Forward-looking statements involve risks and uncertainties, which are based on current expectations as of the date of this release and subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including the failure to realize the expected benefits of the acquisition, or the Company’s failure to fulfil the listing conditions imposed by the Toronto Stock Exchange. Additional information about these assumptions and risks and uncertainties is contained under “Risk Factors and Uncertainties” in the Company’s latest annual information form filed on March 6, 2024, which is available under the Company’s SEDAR profile at http://www.sedar.com, and in other filings that the Company has made and may make with applicable securities authorities in the future. Forward-looking statements contained herein are made only as to the date of this press release and we undertake no obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. The Toronto Stock Exchange has not reviewed, approved or disapproved the content of this news release.

INVESTOR CONTACT
Curaleaf Holdings, Inc.
Camilo Lyon, Chief Investment Officer
[email protected]

MEDIA CONTACT
Curaleaf Holdings, Inc.
Tracy Brady, SVP Corporate Communications
[email protected]

View original content:https://www.prnewswire.co.uk/news-releases/curaleaf-completes-acquisition-of-northern-green-canada-302123010.html

Continue Reading

Trending on Grassnews

GrassNews.net: Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with GrassNews.net..

Contact us: [email protected]

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania